Article Details

UCB announces extended FDA approvals for BIMZELX for Inflammatory Autoimmune Diseases

Retrieved on: 2024-09-26 20:21:17

Tags for this article:

Click the tags to see associated articles and topics

UCB announces extended FDA approvals for BIMZELX for Inflammatory Autoimmune Diseases. View article details on hiswai:

Excerpt

The U.S. biopharma company UCB announced this week that the FDA has extended its approval of BIMZELX (bimekizumab-bkzx) for the treatment of four ...

Article found on: www.biopharma-reporter.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo